Thomas Gad - 18 May 2022 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role: Founder, President Interim Chief Executive Officer and Head of Business Development & Strategy, Director
Signature: /s/ THOMAS GAD
Issuer symbol: YMAB
Transactions as of: 18 May 2022
Transactions value $: $0
Form type: 4
Filing time: 19 May 2022, 16:16:08 UTC
Previous filing: 09 Feb 2022
Next filing: 19 Jan 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	YMAB	Employee Stock Option (right to buy)	Award	$0	+60K		$0.00	60K	18 May 2022	Common stock	60K	$9.52	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F2	The stock option shall vest and become exercisable as to 25% of the shares subject to the option on May 18, 2023, and thereafter vests and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Remarks:

Founder, President Interim Chief Executive Officer and Head of Business Development & Strategy